Compare Chevron Corp (CVX) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chevron Corp vs Ginkgo Bioworks Holdings Inc — how do they compare? Chevron Corp trades at $179.81 (market cap $361.99B), while Ginkgo Bioworks Holdings Inc trades at $9.12 (market cap $590.53M). The key difference: Chevron Corp is far larger — about 613× Ginkgo Bioworks Holdings Inc's market cap, and Chevron Corp pays a 3.92% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| CVX | DNA | |
|---|---|---|
Market Cap | $361.99B | $590.53M |
Volume | 9,807,834 | — |
Sector | Energy | Health |
52-Week High | $211.14 | $16.14 |
52-Week Low | $146.72 | $5.48 |
Enterprise Value | $402.09B | $627.78M |
Dividend Yield | 3.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVX trades at $182.21, up 3.29% on the day, with bullish technical signals from moving averages and ADX indicators. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.41 surpassing the $1.00 estimate. The company maintains strong operating cash flow of $33.94 billion in 2025 and announced a $13.8 billion investment in Argentina's Vaca Muerta shale project, signaling growth commitment.
The outlook remains positive with a consensus price target of $207.56, implying 13.9% upside. High oil prices and strategic expansions support growth, but declining profit margins and geopolitical tensions pose risks. Analyst sentiment is strongly bullish with 62% buy ratings, though investors should monitor debt levels, which rose to 12.35% of assets in 2025.
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
